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Novelty and Impact (75 words): This is the first genome-wide association analysis examining age-at-
diagnosis--which is strongly associated with incidence and prognosis--and germline risk variants in 
glioblastoma. We detected a higher frequency of germline variants associated with lower grade gliomas 
(LGG) in the younger cohort, as well as high frequency of LGG-like somatic variants in The Cancer 
Genome Atlas GBM cohort. Age-specific differences in phenotype should be taken into consideration 
when molecular classification data is not available 
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ABSTRACT (250/250 WORDS) 
Glioblastoma (GBM) is the most common malignant brain tumor in the United States. Incidence of GBM 
increases with age, and younger age-at-diagnosis is significantly associated with improved prognosis. 
While the relationship between candidate GBM risk SNPs and age-at-diagnosis has been explored, 
genome-wide association studies (GWAS) have not previously been stratified by age. Potential age-
specific genetic effects were assessed in autosomal SNPs for GBM patients using data from four previous 
GWAS. Using age distribution tertiles (18-53, 54-64, 65+) datasets were analyzed using age-stratified 
logistic regression to generate p values, odds ratios (OR), and 95% confidence intervals (95%CI), and 
then combined using meta-analysis. There were 4,512 total GBM cases, and 10,582 controls used for 
analysis. Significant associations were detected at two previously identified SNPs in 7p11.2 (rs723527 
[p54-63=1.50x10
-9
, OR54-63=1.28, 95%CI54-63=1.18-1.39; p64+=2.14x10
-11
, OR64+=1.32, 95%CI64+=1.21-1.43] 
and rs11979158 [p54-63=6.13x10
-8
, OR54-63=1.35, 95%CI54-63=1.21-1.50; p64+=2.18x10
-10
, OR64+=1.42, 
95%CI64+=1.27-1.58]) but only in persons >54. There was also a significant association at the previously 
identified lower grade glioma (LGG) risk locus at 8q24.21 (rs55705857) in persons ages 18-53 (p18-
53=9.30x10
-11
, OR18-53=1.76, 95%CI18-53=1.49-2.10). Within The Cancer Genome Atlas (TCGA) there was 
higher pre alence of ‘LGG’-like tumor characteristics in GBM samples in those 18-53, with IDH1/2 
mutation frequency of 15%, as compared to 2.1% [54-63] and 0.8% [64+] (p=0.0005). Age-specific 
differences in cancer susceptibility can provide important clues to etiology. The association of a SNP 
known to confer risk for IDH1/2 mutant glioma and higher prevalence of IDH1/2 mutation within 
younger individuals 18-53 suggests that more younger indi iduals may present initially  ith ‘secondary 
glioblastoma.’ 
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INTRODUCTION 
Glioma is the most common type of malignant primary brain tumor (PBT) in the United States (US), with 
an average annual age-adjusted incidence of 6.0 per 100,000 from 2010-2014.
1
 Glioblastoma (GBM) 
represents the majority of gliomas diagnosed in adults (approximately 62% of all gliomas diagnosed in 
persons 18+). While these tumors are most common in older adulthood, they also occur in younger adults. 
Persons diagnosed with GBM at younger ages have significantly better survival than those who are 
diagnosed at older ages, with 5-year survival of 19.0% in persons 20-44 as compared to 1.8% in persons 
65+. 
 
Gliomas are classified using histologic criteria determined by the World Health Organization (WHO) and 
broadly classified according to apparent cell of origin (astrocyte vs oligodendrocyte), and graded from 
grade I-IV, where increasing WHO grade is associated with increasing malignant behavior.
2
 GBMs are 
WHO grade IV astrocytomas. Recent molecular characterization of gliomas (including both GBM and 
LGG) has determined that gliomas can be more precisely stratified using two common alterations: 
mutation in isocitrate dehydrogenase 1/2 (IDH1/2) and loss of the 1p/19q.3 The vast majority of GBMs 
(~95%) do not have either alteration.
4
 
 
Many environmental exposures have been investigated as risk factors for glioma, but the only consistently 
identified risk factors are ionizing radiation (which increases risk), and history of allergies (which 
decreases risk).
5
 The contribution of common low-penetrance single nucleotide polymorphisms (SNPs) to 
the heritability of glioma in persons with no documented family history is estimated to be ~25%.
6
 A 
recent glioma genome-wide association study (GWAS) meta-analysis validated 12 previously reported 
risk loci, and identified 13 new risk loci. These 25 loci in total are estimated to account for ~30% of 
heritable risk.
7
 This suggests that there are both undiscovered environmental risk (which accounts for 
~75% of risk variance) and genetic risk factors (accounting for ~70% of heritable risk).
6, 7
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Many previously discovered glioma risk loci have histology-specific associations,
7
 but the effect of these 
loci on age-at-diagnosis has not been systematically explored. An age-specific analysis could potentially 
increase power to detect new variants that may be associated with age-at-diagnosis, and more accurately 
quantify the age-specific effect sizes of previously-identified variants.
8
 This analysis aims to explore the 
associations between genetic risk and age-at-diagnosis in GBM only.  
METHODS 
This study was approved locally by the institutional review board (IRB) at University Hospitals 
Cle eland Medical Center and by each participating study site’s I B. In this study, data on GBM cases 
were combined from four prior glioma GWAS.
7, 9-11
  Due to the molecular heterogeneity of LGGs and the 
lack of molecular subtype data available within these datasets, this analysis focused on GBM only. After 
quality control was completed, the combined dataset contained 4,523 GBM cases (See Supplementary 
Table 1 for study characteristics). Details of data collection, genotyping, and imputation for included 
GWAS datasets are available in previous publications.
7, 9-11
 All datasets have previously undergone 
standard GWAS QC, and duplicate and related individuals have been excluded (as described in Melin, et 
al.
7
). Demographic information and somatic features for GBM cases included in The Cancer Genome 
Atlas (TCGA, see Supplementary Table 1 for characteristics) were obtained from the final dataset used 
for the TCGA pan-glioma analysis. 4, 12 
 
Single-SNP association results were generated for the ~12,000 SNPs (INFO≥0.7, MAF≥0.01) identified 
as having a nominally significant (p<5x10
-4
) association with all glioma, GBM, or LGG.  SNPs found to 
have nominally significant association with non-GBM glioma were included to assess potential 
association of these SNPs with GBM in younger individuals. GBM cases were divided into age 
strata based on the tertiles of the case age-at-diagnosis distribution (18-53, 54-63, and 64+) for case-
control analyses (see Figure 1a for overview of study design) and each age strata was compared against 
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all controls.
13
 The data were analyzed using age-stratified logistic regression models in SNPTEST 
adjusted for sex and the number of principal components that significantly differed between cases and 
controls within each study.
7
 Single-study results were combined via meta-analysis using an inverse-
variance weighted fixed effects method in META.  Results from the case-control analysis were 
considered statistically significant at the p<5x10
-8
 level (using a Bonferroni correction for 1,000,000 
tests). 
 
In order to identify individual SNPs with age-at-diagnosis effects, a case-only analysis using age-at-
diagnosis as a continuous phenotype was conducted using linear regression in SNPTEST. This analysis 
assumed an additive model to estimate beta, standard error, and p values (see Figure 1b for overview of 
study design). All models were adjusted for sex, and both GICC and Gliomascan were adjusted for 
principal components due to genomic inflation (GICC: λunadjusted=1.02, λadjusted=1.01; SFAGS-GWAS: 
λunadjusted=1.01, λadjusted=1.01; MDA-GWA : λunadjusted=0.99, λadjusted=0.99; Gliomascan: λunadjusted=1.04, 
λadjusted=1.01). Results were combined using both inverse-variance weighted fixed effects and random 
effects meta-analysis in META. Results were considered statistically significant at p<4.17x10
-6
 
(Bonferroni correction for 12,000 tests). Analyses were also run in two older age-groups (median and 
above median age, ages 54+) to evaluate whether a dose-response curve exists between genotype and age-
at-diagnosis, or if significant associations were identifying differences between the youngest versus oldest 
age groups. All figures were generated using R 3.3.2, qqman, and ggplot.
14-17
 
 
TCGA GBM cases were divided into the same three age strata for analysis. Only newly diagnosed, white 
non-Hispanic cases with no neo-adjuvant treatment or prior cancer were used. Demographic 
characteristics, molecular classification and somatic alterations data was obtained from Ceccarelli, et al.
12
 
Age-specific differences in frequency of molecular markers by age were tested using chi square tests. 
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RESULTS 
There were 4,512 total GBM cases, and 10,582 controls in the four included GWAS datasets 
(Supplementary Table 1). Overall, 62.8% of GBM cases were male, with a mean age-at-diagnosis of 
57.5.  
 
No new risk loci were identified in an age-stratified genome-wide scan.  SNPs in 5/25 previously 
identified risk loci reached genome wide significance (p<5x10
-8
, Bonferroni correction for 1,000,000 
tests) in at least one age strata, including three previously identified SNPs in 7p11.2 (Table 1, 
Supplementary Figures 1-2). Results for SNPs in 5p15.33, 9p21.3, 17p.13.1, and 20q13.33 were similar 
in all three age-groups.   Among the three identified SNPs in 7p11.2, results for rs75061358 were similar 
in all age-groups.  Two other SNPs (rs723527 and rs11979158) were nominally significant in the age 18-
53 strata, and reached genome-wide significance in the age 54-63, and age 64+ stratum. The risk locus at 
8q24.21 reached genome-wide significance in the 18-53 age-group (p=9.30x10
-11
), while the effect of this 
SNP was null in the other age-groups. The OR for the 18-53 year age-group was 1.76 (95%CI: 1.49-
2.10). There was variability of effect by study, though tests for heterogeneity were not significant 
(Supplementary Figure 3, Supplementary Table 2).  In order to assess whether confounding between 
age-at-diagnosis and histologic classification may exist, a sensitivity analysis was performed using only 
individuals diagnosed after 2000 (Supplementary Table 3).  Among individuals 18-53 diagnosed after 
2000 only, there was still a genome-wide significant signal for the SNP at 8q24.21 (p=5.47x10
-10
, 
OR=1.84 [95%CI=1.52-2.23]). 
 
A case-only analysis was conducted in previously-identified nominally significant SNPs with age-at-
diagnosis as the outcome variable, and associations were considered significant at p<4.17x10
-6
 
(Bonferroni correction for 12,000 tests). There were two peaks that reached statistical significance in the 
fixed effects meta-analysis at 8q24.21, and 11q23.3 (Supplementary Figure 4a). When a random effects 
meta-analysis was carried out, only the peak at 8q24.21 reached the significance threshold 
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(Supplementary Figure 4b). The previously identified SNP at 8p24.21 was significantly associated with 
younger age-at-diagnosis, with an approximate decrease in age-at-diagnosis of 3 years for each risk allele 
(prandom=3.70x10
-6
, pfixed=1.51x10
-11
) (Figure 2, Supplementary Table 4). When this association was 
evaluated in cases ages 54+ only, the association was null. There was a nominal association in the case-
only analysis between age-at-diagnosis and the previously identified SNP at 5p15.33 (rs10069690) and 
GBM (pfixed =0.0033, prandom =0.0053) with an increase in age of diagnosis of 0.76 years for each risk 
allele.  When the case-only analysis was limited to the two older age-groups (individuals >53 years old), 
there was no significant association between this SNP and age-at-diagnosis (pfixed=0.4818, 
prandom=0.4814).  In the fixed effects meta-analysis, two previously identified SNPs in 11q23.3 were 
significantly associated with older age-at-diagnosis.  For both SNPs (rs12803321 and rs498872), each risk 
allele was associated with an increase of approximately 1.5 years in age-at-diagnosis. There was some 
heterogeneity by study for both of the evaluated SNPs at 11q23.3 (rs12803321 phet=5.5x10
-5
; rs498872 
phet=0.0138), and in the random effects meta-analysis, the associations at both of these SNPs no longer 
met the threshold for significance.  In the subset of cases ages 54+, rs498872 remained nominally 
significantly associated with age-at-diagnosis (pfixed=0.0056, prandom=0.0225), with an estimated 0.52-year 
increase in age of diagnosis for each risk allele. There was no association between rs12803321 and age-
at-diagnosis in the older subset. There was a nominal association between rs11979158 and younger age-
at-diagnosis (pfixed= 0.0021, prandom= 0.0021), but this association was null in the subset of cases ages 54+.  
 
Age-at-diagnosis differed significantly by molecular subgroup within the TCGA GBM dataset. Median 
age-at-diagnosis was lowest in IDH1/2 mutant GBM samples (38.5) and highest in IDH1/2 wild-type 
samples (62.0). Within the youngest age-group of individuals 18-53, 15/100 individuals had IDH1/2 
mutant tumors (15%), as compared to 2/94 in those 54-63 (2.1%), and 1/121 in those 64+ (0.8%). 
Frequency of TERT mutation increased with increasing age, with the highest frequency of this feature 
(94%) occurring in the oldest age-group. Overall, GBM samples in the youngest age-group appeared to be 
more “LGG-like” as compared to those in the t o older groups.3, 12 
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DISCUSSION 
This is the first genome-wide age-specific analysis focused specifically on the relationship between 
germline risk variants and age-at-diagnosis in GBM, and leverages multiple existing glioma GWAS 
datasets. This study demonstrated that there are age-related differences in frequency of known heritable 
genetic risk variants in glioma, largely driven by differences in those less than 54 years of age. While 
these results replicate some previously identified associations,
18
 the age-stratified approach reveals 
potential phenotypic differences between persons diagnosed with these tumors at younger ages. Now that 
molecular markers are routinely incorporated in glioma diagnosis, incorporation of these more precise 
phenotype classifications into GWAS is necessary in order to understand the pathways and mechanisms 
through which these risk variants confer increased susceptibility for GBM, and the extent to which these 
may vary by age.  
 
Previous studies have consistently reported that alterations in telomerase-related genes (e.g. TERT and 
RTEL1) are associated with increased age-at-diagnosis for gliomas.18 This analysis found that variants in 
TERT and RTEL1 reached genome-wide significance among all three age cohorts, with no substantial 
difference in estimated effect by age. In the case-only analysis, there was a nominally significant 
association between rs10069690 (TERT, pRandom=0.0053) and increased age-at-diagnosis, with an increase 
of 0.76 years of age per risk allele.  There was no significant association between rs2297440 (RTEL1, 
pRandom=0.0512) and increased age-at-diagnosis. The analysis also reported association between risk 
alleles in PHLDB1 and decreased age-at-diagnosis.18 There was a nominally significant association 
between these SNPs in PHLDB1 and age-at-diagnosis in a case-only analysis, but when analysis was 
limited to those 54 years of age and older, the effect of these SNPs on age-at-diagnosis was null, 
suggesting that phenotypic differences between the younger and older cohort may be driving the observed 
allele frequency differences rather than a true effect on age-at-diagnosis. 
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Two SNPs at the 7p11.2 locus showed variation in association by age, with similar effects in all included 
studies (Supplementary Figures 4-5).  These variants were within one of two previously identified 
independent glioma risk loci located near EGFR, which is most strongly associated with risk for GBM.7, 19 
Variation in an observed association by age with a SNP at 8q24.21 was present. This SNP has been 
previously associated with non-GBMs—in particular low-grade tumors that have IDH1/2 mutation and 
1p/19q co-deletion—and a significant association between this SNP and GBM has not been previously 
reported.  While IDH1/2 mutation is most common in LGG (where ~80% of tumors have this alteration), 
only a minority of GBM (~5%) have this alteration.
12
  Among individuals with tumors that appear 
histologically to be GBM, IDH1/2 mutation is known to occur more commonly in younger individuals.20 
Among the TCGA GBM set, IDH1/2 mutation occurred in 15% of cases in individuals 18-53, as 
compared to 2.1% and 0.8% in individuals 54-63 and 64+, respectively (p=0.0005).  These mutations 
occur very early in gliomagenesis, and as a result represent an entity that is distinct from IDH1/2 wild-
type GBM. IDH1/2 mutation is generally considered to be a marker of ‘secondary GBM’, or GBM that 
has progressed from a previously undiagnosed LGG.
21
 Individuals with these ‘secondary GBMs’ have 
been consistently reported to be younger than those with primary GBM.
21
 
 
All GBM cases from the included four GWAS datasets were recruited at time of first diagnosis, and the 
assigned diagnoses represent the primary tumor type. Most glioma GWAS have categorized phenotype 
based on histologic criteria only. The significant inter-rater variability in diagnosis of glioma has been 
well documented,
22
 though the extent of misclassification is more significant in LGG.
23
  Diagnostic 
technologies and histologic classification criteria of GBM has changed over the recruitment periods for 
the four included studies (1974-2013, varying). While classification using IDH1/2 mutation and 1p19q 
co-deletion was not codified until the release of the 2016 WHO classification scheme, these markers were 
gradually adopted for use in glioma diagnosis prior to the release of this scheme. Changing classification 
criteria over time as well as gradual adoption of molecular markers could have resulted in a small number 
of some earlier cases that may not have been classified as GBM if diagnosed during a later period.  The 
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incorporation of molecular markers into classification criteria significantly improves diagnostic accuracy 
and consistency.
24
 These markers should be incorporated into glioma GWAS in order to better understand 
the ways that germline markers confer risk, and for which tumor types they increase susceptibility. 
 
An alternate approach to this analysis could be to include age-at-diagnosis as an interaction term in 
logistic regression. Use of interaction models often requires that the effect on the association reach a 
stringent p-value to correct for multiple testing, and as a result these methods may miss effects that are 
not very large.
25
 Stratified analyses decrease sample size and therefore power, but these analyses may 
more successfully identify associations of small effect size that may not be identified using interaction 
models. 
 
CONCLUSIONS 
Age-specific differences in cancer susceptibility can provide important clues to etiology, and these 
differences can be leveraged for discovery in genetic association studies. This analysis identified potential 
age-specific effects in two previous identified glioma risk loci (7p11.2, and 8q24.21). The association of a 
SNP known to confer risk for IDH1/2 mutant glioma with GBM within individuals 18-53 suggests that a 
substantial portion of younger individuals included in GBM research may present initially with 
‘secondary GBM.’ The higher prevalence of IDH1/2 mutant GBM within this younger age-group is also 
evident within TCGA GBMs. While age is known to be a strong factor associated with differences in 
incidence and prognosis for GBM, the results of this analysis suggest that younger age is associated with 
phenotype and risk of GBM.   
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Glioma scan group comprised: Laura E. Beane Freeman, Stella Koutros, Demetrius Albanes, Kala 
Visvanathan, Victoria L. Stevens, Roger Henriksson, Dominique S. Michaud, Maria Feychting, Anders 
Ahlbom , Graham G. Giles Roger Milne , Roberta McKean-Cowdin, Loic Le Marchand, Meir Stampfer, 
Avima M. Ruder, Tania Carreon, Goran Hallmans, Anne Zeleniuch-Jacquotte, J. Michael Gaziano, 
Howard D. Sesso, Mark P. Purdue, Emily White , Ulrike Peters, Howard D. Sesso, Julie Buring. 
UK10K data generation and access was organized by the UK10K consortium and funded by the 
Wellcome Trust. The results here are in part based upon data generated by the TCGA Research Network: 
http://cancergenome.nih.gov/. 
We are grateful to all the patients and individuals for their participation and we would also like to thank 
the clinicians and other hospital staff, cancer registries and study staff in respective centers who 
contributed to the blood sample and data collection. 
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FIGURE LEGENDS 
Figure 1. Study schematic for a) age-stratified case-control analyses, and b) case-only analyses 
Figure 2. Case only estimates for SNPs identified as being significantly associated with age-at-diagnosis 
in this or prior analyses in a) all ages, b) cases ages 54+ 
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TABLES 
Table 1 Previously identified glioma risk loci and histology-specific odds ratios (OR) and 95% confidence intervals (95%CI) stratified by age. 
SNP (Locus) Risk Allele 
Associated 
Gene 
Diagnosis Ages 18-53 
(Below Median Age-at-diagnosis) 
Diagnosis Ages 54-63  
(Median Age-at-diagnosis) 
Diagnosis Ages 64+ 
(Above Median Age-at-diagnosis) 
P OR  (95%CI) Phet Q I
2
 P OR  (95%CI) Phet Q I
2
 P OR  (95%CI) Phet Q I
2
 
rs10069690 (5p15.33)  C/T TERT 3.79x10-18 1.51 
(1.38-1.66) 
0.7138 1.36 0.00 4.05x10-33 1.78 
(1.62-1.95) 
0.5182 2.27 0.00 4.59x10-31 1.72 
(1.57-1.89) 
0.0664 7.18 58.21 
rs75061358 (7p11.2) T/G EGFR 6.78x10-12 1.67 
(1.44-1.94) 
0.7282 1.30 0.00 2.44x10-12 1.70 
(1.47-1.97) 
0.4542 2.62 0.00 3.67x10-16 1.85 
(1.60-2.15) 
0.3607 3.21 6.48 
rs723527 (7p11.2) A/G EGFR 1.37x10-5 1.19 
(1.10-1.29) 
0.2992 3.67 18.29 1.50x10-9 1.28 
(1.18-1.39) 
0.6193 1.78 0.00 2.14x10-11 1.32 
(1.21-1.43) 
0.2263 4.35 30.99 
rs11979158 (7p11.2) A/G EGFR 2.47x10-4 1.22 
(1.10-1.36) 
0.8084 0.97 0.00 6.13x10-8 1.35 
(1.21-1.50) 
0.8007 1.00 0.00 2.18x10-10 1.42 
(1.27-1.58) 
0.8696 0.72 0.00 
rs55705857 (8q24.21) A/G CCDC26 9.30x10-11 1.76 
(1.49-2.10) 
0.3040 3.63 17.41 0.4225 1.08 
(0.90-1.28) 
0.5380 2.17 0.00 0.0280 1.21 
(1.02-1.44) 
0.0811 6.73 55.41 
rs634537 (9p21.3) T/G CDKN2B 9.50x10-17 1.40 
(1.29-1.51) 
0.9589 0.31 0.00 3.72x10-19 1.44 
(1.33-1.56) 
0.2814 3.82 21.49 2.62x10-15 1.38 
(1.27-1.49) 
0.0503 7.80 61.54 
rs498872 (11q23.3) 
A/G PHLDB1 0.0428 1.09 
(1.00-1.19) 
0.4940 2.40 0.00 0.9587 1.00 
(0.92-1.09) 
0.9194 0.50 0.00 0.0284 0.91 
(0.84-0.99) 
0.0537 7.66 60.82 
rs12803321 (11q23.3) 
G/C PHLDB1 0.0062 1.12 
(1.03-1.22) 
0.7465 1.23 0.00 0.1786 0.94 
(0.87-1.03) 
0.4459 2.67 0.00 0.0795 0.93 
(0.85-1.01) 
0.2666 3.95 24.11 
rs78378222 (17p13.1) T/G TP53 8.65x10-16 3.80 
(2.74-5.25) 
0.7013 1.42 0.00 2.87x10-8 2.54 
(1.83-3.53) 
0.5256 2.23 0.00 4.13x10-13 3.26 
(2.37-4.48) 
0.0131 10.76 72.12 
rs2297440 (20q13.33) T/C RTEL1 8.21x10-13 1.41 
(1.28-1.55) 
0.5492 2.11 0.00 7.35x10-19 1.55 
(1.40-1.70) 
0.3556 3.24 7.50 1.49x10-14 1.45 
(1.32-1.60) 
0.3719 3.13 4.19 
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 The authors performed the first genome-wide association analysis examining 
age-at-diagnosis and germline risk variants in glioblastoma. They report a higher 
frequency of germline variants associated with lower grade gliomas (LGG) in the 
younger cohort (age 18–53), as well as high frequency of LGG-like somatic 
variants in The Cancer Genome Atlas Glioblastoma cohort. This could indicate 
that glioblastoma at a younger age might more often evolve from an LGG 
(secondary glioblastoma) than at an older age and should be taken into 
consideration when molecular classification is not available. 
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